Clinical Trial: RITUXIMAB BS Intravenous Infusion 100mg?500mg [Pfizer] Post-marketing Database Study
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Lymphoma
Study Type: OBSERVATIONAL
Official Title: RITUXIMAB BS Intravenous Infusion 100mg?500mg [Pfizer] Post-marketing Database Study
Brief Summary:
To evaluate the incidence of the outcomes for the safety specifications in patients of Medical Data Vision database in Japan diagnosed with CD20 positive B-cell non- Hodgkin's lymphoma who were treated with Rituximab Pfizer to compare it with outcomes in patients who were treated with Rituxan from 01 January 2020 through 31 December 2024
Read more